Exostar and SAFE-BioPharma Association announced a new partnership that will enable Exostar to issue non-public key infrastructure (PKI) identity credentials at Levels of Assurance 2 and 3 (LOA 2, LOA 3) to its community of life sciences and healthcare customers via SAFE-BioPharma’s government approved Trust Framework Provider (TFP) service.

In today’s evolving marketplace, life sciences and healthcare companies are faced with the challenge of securely enabling business processes in the cloud while ensuring regulatory compliance and better alignment with evolving governmental online processes.  The partnership will enable Exostar to issue LOA 2 and LOA 3 identity credentials, under the SAFE-BioPharma Trust Framework.  Companies can leverage globally-accepted identity credentials to provide secure and trusted access to proprietary toolsets, analytics, and other internal/external applications in the cloud to their business partners, outside researchers, government agencies, or even competitors.

The benefits of the new partnership include, accelerated development of solutions, increasing profit potential;. Use of a single credential with all partners, eliminating the need for multiple digital identities and passwords; Reduced costs by replacing physical identity credentials with cloud-based credentials that can be accessed and used from any Internet connection.  Elimination of redundant paper audits.
Faster organisation and individual on-boarding. Increased agility by eliminating site-to-site Virtual Private Networks while maintaining privacy and security.
Smoother operations resulting from Web single sign-on (SSO).

"This is great news for the 500-plus organisations who currently utilise our Life Sciences Identity Hub to collaborate, as well as the rest of the industry looking to outsource development, testing or supply chain initiatives.  The ability to utilise a range of identity credentials compliant with the SAFE-BioPharma standard will create more business opportunities, and greatly increase the number of use cases possible across the extended life sciences and healthcare communities," said Daniel Pfeifle, vice president, Sales and Marketing, Exostar.

"Using SAFE-BioPharma compliant identities to conduct collaborative business processes via the Exostar Identity Hub offers life sciences and healthcare companies a platform to securely collaborate and a vehicle to transform business processes to the 21st Century digital world," said Mollie Shields-Uehling, president and chief executive officer, SAFE-BioPharma Association.

Exostar powers secure business-to-business information sharing, collaboration and business process integration throughout the value chain.  Exostar supports the complex trading needs of many of the world's largest companies in aerospace and defense, life sciences, and other industries.  Exostar’s cloud-based identity assurance products and business applications reduce risk, improve agility and strengthen trading partner relationships and profitability for over 100,000 companies in 150 countries worldwide.  The Exostar community includes market leaders such as AstraZeneca, BAE Systems, Bell Helicopter, The Boeing Company, BT, Computer Sciences Corporation, Lockheed Martin Corp., Merck, Newport News Shipbuilding, Northrop Grumman, Raytheon Co. and Rolls-Royce.